메뉴 건너뛰기




Volumn 118, Issue 21, 2012, Pages 5265-5269

Evaluation of residual CD34+Ph+ progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first-line nilotinib therapy

Author keywords

CD34+ cells; chronic myeloid leukemia; leukemic stem cells; nilotinib

Indexed keywords

BCR ABL PROTEIN; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR;

EID: 84867842686     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27506     Document Type: Article
Times cited : (11)

References (13)
  • 1
    • 78049528573 scopus 로고    scopus 로고
    • Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: The prospective, multicentre Stop Imatinib (STIM) trial
    • et al; Intergroupe Français des Leucémies Myéloïdes Chroniques.
    • Mahon FX, Réa D, Guilhot J, et al. Intergroupe Français des Leucémies Myéloïdes Chroniques. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010; 11: 1029-1035.
    • (2010) Lancet Oncol. , vol.11 , pp. 1029-1035
    • Mahon, F.X.1    Réa, D.2    Guilhot, J.3
  • 2
    • 0038454621 scopus 로고    scopus 로고
    • Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment
    • Bhatia R, Holtz H, Niu N, et al. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood. 2003; 101: 4701-4707.
    • (2003) Blood. , vol.101 , pp. 4701-4707
    • Bhatia, R.1    Holtz, H.2    Niu, N.3
  • 3
    • 39149108468 scopus 로고    scopus 로고
    • CD34+/Ph+ cells are still detectable in chronic myeloid leukemia patients with sustained and prolonged complete cytogenetic remission during treatment with imatinib mesylate
    • Bocchia M, Ippoliti M, Gozzetti A, et al. CD34+/Ph+ cells are still detectable in chronic myeloid leukemia patients with sustained and prolonged complete cytogenetic remission during treatment with imatinib mesylate. Leukemia. 2008; 22: 426-428.
    • (2008) Leukemia. , vol.22 , pp. 426-428
    • Bocchia, M.1    Ippoliti, M.2    Gozzetti, A.3
  • 4
    • 13844251975 scopus 로고    scopus 로고
    • Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl
    • Weisberg E, Manley PW, Breitenstein W, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell. 2005; 7: 129-141.
    • (2005) Cancer Cell. , vol.7 , pp. 129-141
    • Weisberg, E.1    Manley, P.W.2    Breitenstein, W.3
  • 5
    • 36348968931 scopus 로고    scopus 로고
    • Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance
    • Kantarjian HM, Giles F, Gattermann N, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood. 2007; 110: 3540-3546.
    • (2007) Blood. , vol.110 , pp. 3540-3546
    • Kantarjian, H.M.1    Giles, F.2    Gattermann, N.3
  • 6
    • 73949145209 scopus 로고    scopus 로고
    • Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia
    • et al; GIMEMA CML Working Party.
    • Rosti G, Palandri F, Castagnetti F, et al. GIMEMA CML Working Party. Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. Blood. 2009; 114: 4933-4938.
    • (2009) Blood. , vol.114 , pp. 4933-4938
    • Rosti, G.1    Palandri, F.2    Castagnetti, F.3
  • 7
    • 77953691179 scopus 로고    scopus 로고
    • Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia
    • et al; ENESTnd Investigators.
    • Saglio G, Kim DW, Issaragrisil S, et al. ENESTnd Investigators. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010; 362: 2251-2259.
    • (2010) N Engl J Med. , vol.362 , pp. 2251-2259
    • Saglio, G.1    Kim, D.W.2    Issaragrisil, S.3
  • 8
    • 80052383499 scopus 로고    scopus 로고
    • Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukemia: 24-months minimum follow-up of the phase 3 randomised ENESTnd trial
    • Kantarjian HM, Hochhaus A, Saglio G, et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukemia: 24-months minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol. 2011; 12: 841-851.
    • (2011) Lancet Oncol. , vol.12 , pp. 841-851
    • Kantarjian, H.M.1    Hochhaus, A.2    Saglio, G.3
  • 9
    • 42349116071 scopus 로고    scopus 로고
    • Enhanced BCR-ABL kinase inhibition does not result in increased inhibition of downstream signaling pathways or increased growth suppression in CML progenitors
    • Konig H, Holtz M, Modi H, et al. Enhanced BCR-ABL kinase inhibition does not result in increased inhibition of downstream signaling pathways or increased growth suppression in CML progenitors. Leukemia. 2008; 22: 748-755.
    • (2008) Leukemia. , vol.22 , pp. 748-755
    • Konig, H.1    Holtz, M.2    Modi, H.3
  • 10
    • 14444282451 scopus 로고    scopus 로고
    • CD34+AC133+ cells isolated from cord blood are highly enriched in long-term culture-initiating cells, NOD/SCID-repopulating cells and dendritic cell progenitors
    • de Wynter EA, Buck D, Hart C, et al. CD34+AC133+ cells isolated from cord blood are highly enriched in long-term culture-initiating cells, NOD/SCID-repopulating cells and dendritic cell progenitors. Stem Cells. 1998; 16: 387-396.
    • (1998) Stem Cells. , vol.16 , pp. 387-396
    • De Wynter, E.A.1    Buck, D.2    Hart, C.3
  • 11
    • 33745603988 scopus 로고    scopus 로고
    • Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: Review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results
    • Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006; 108: 28-37.
    • (2006) Blood. , vol.108 , pp. 28-37
    • Hughes, T.1    Deininger, M.2    Hochhaus, A.3
  • 12
    • 34548793961 scopus 로고    scopus 로고
    • An international study to standardize the detection and quantitation of BCR-ABL transcripts from stabilized peripheral blood preparation by quantitative RT-PCR
    • Müller MC, Saglio G, Lin F, et al. An international study to standardize the detection and quantitation of BCR-ABL transcripts from stabilized peripheral blood preparation by quantitative RT-PCR. Haematologica. 2007; 92: 970-973.
    • (2007) Haematologica. , vol.92 , pp. 970-973
    • Müller, M.C.1    Saglio, G.2    Lin, F.3
  • 13
    • 81555214617 scopus 로고    scopus 로고
    • Persistence of leukemia stem cells in chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib treatment for 5 years
    • Chu S, Lin A, McDonald T, et al. Persistence of leukemia stem cells in chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib treatment for 5 years. Blood. 2011; 118: 5565-5572.
    • (2011) Blood. , vol.118 , pp. 5565-5572
    • Chu, S.1    Lin, A.2    McDonald, T.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.